Abstract
Vascular endothelial growth factor (VEGF) causes vasodilation in adult models of peripheral vascular disease and myocardial ischemia through the acute release of nitric oxide (NO). However, the hemodynamic effects of VEGF and its effects on NO production have not been studied in the developing lung circulation. We hypothesized that VEGF causes fetal pulmonary vasodilation, and that its actions are mediated through the release of endogenous NO. We performed surgery in 16 fetal lambs (125–135 d gestation; term = 147 d), and placed catheters in the main pulmonary artery, aorta, and left atrium to measure pressures. An ultrasonic flow transducer was placed on the left pulmonary artery (LPA) to measure blood flow, and a catheter was placed in the LPA for local drug infusion. Pulmonary vascular resistance in the left lung was calculated as pulmonary artery pressure minus left atrial pressure divided by LPA flow. Fetal lambs were treated with brief infusions of recombinant human VEGF (dose, 0.5–2.0 μg) into the LPA. Recombinant human VEGF infusions acutely increased LPA flow by up to 3-fold (p < 0.02) and decreased pulmonary vascular resistance by 65% (p < 0.05) in a dose-related fashion, without affecting aortic pressure or heart rate. To determine the mechanism of VEGF-induced vasodilation, we studied the effects of nitro-l-arginine, an NO synthase inhibitor, and LY294002, a phosphatidylinositol-3-kinase inhibitor, on the response to VEGF. We found that pretreatment with either nitro-l-arginine or LY294002 completely inhibited the vasodilator response to recombinant human VEGF (p < 0.005). These findings suggest that recombinant human VEGF causes fetal pulmonary vasodilation, and that this response is likely mediated by the release of NO through activation of phosphatidylinositol-3-kinase.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- VEGF:
-
vascular endothelial growth factor
- NO:
-
nitric oxide
- NOS:
-
NO synthase
- MPA:
-
main pulmonary artery
- Ao:
-
aorta
- LA:
-
left atrium
- LPA:
-
left pulmonary artery
- PVR:
-
pulmonary vascular resistance
- MPAP:
-
MPA pressure
- AoP:
-
Ao pressure
- LAP:
-
LA pressure
- L-NA:
-
nitro-l-arginine
- PI-3-K:
-
phosphatidylinositol-3-kinase
- eNOS:
-
endothelial NOS
- Qp:
-
pulmonary blood flow
- BL:
-
baseline
- HR:
-
heart rate
References
Ferrara N, Henzel WJ 1989 Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161: 851–858
Leung DW, Cacianes G, Kuang WJ, Goedel DV, Ferrara N 1989 Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306–1309
Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF 1983 Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983–985
Carmeliet P, Ferrara V, Breier G, Pollefeyt S, Kieckens Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A 1996 Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435–439
Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea SK, Powell-Braxton L, Hillan KJ, Moore MW 1996 Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439–442
Lui W, Ahmad SA, Reinmuth N, Shaheen RM, Sung YD, Fan F, Ellis LM 2000 Endothelial cell survival and apoptosis in the tumor vasculature. Apoptosis 5: 323–328
Gupta K, Kshirsagar S, Li W, Gui L, Ramakrishnan S, Gupta P, Law PY, Gebbel RP 1999 VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res 247: 495–504
Kroll J, Waltenberger J 1998 VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). Biochem Biophys Res Commun 252: 743–746
Bauters C, Asahara T, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, Isner JM 1995 Recovery of disturbed endothelium-dependent flow in the collateral-perfused rabbit ischemic hindlimb after administration of vascular endothelial growth factor. Circulation 91: 2802–2809
Ku DD, Zaleski JK, Liu S, Brock TA 1993 Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol 265: H585–H592
Yang R, Thomas GR, Bunting S, Ko A, Ferrara N, Keyt B, Ross J, Jun H 1996 Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol 27: 838–844
Lopez JJ, Laham RJ, Carrozza JP, Tofukuji M, Sellke FW, Bunting S, Simons M 1997 Hemodynamic effects of intracoronary VEGF delivery: evidence of tachyphylaxis and NO dependence of response. Am J Physiol 273: H1317–H1323
Bauters C, Asahara T, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, Isner JM 1995 Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. J Vasc Surg 21: 314–325
Takeshita S, Zheng LP, Brogi E, Kearney M, Pu LQ, Bunting S, Ferrara N, Symes JF, Isner JM 1994 Therapeutic angiogenesis: a single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 93: 662–670
Banai S, Jaklitsch MT, Shou M, Lazarous DF, Scheinowitz M, Biro S, Epstein SE, Unger EF 1994 Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 89: 2183–2189
Losordo DW, Vale PR, Isner JM 1999 Reperfusion therapy: gene therapy for myocardial angiogenesis. Am Heart J 138: S132–S141
Hood JD, Meininger CJ, Ziche M, Granger HJ 1998 VEGF upregulates ecNOS message, protein and NO production in human endothelial cells. Am J Physiol 274: H1054–H1058
Horowitz JR, Rivard A, Van der Zee R, Hariawala M, Sheriff DD, Esakof DD, Chaudhry GM, Symes JF, Isner JM 1997 Vascular endothelial growth factor/vascular permeability factor produces nitric-oxide dependent hypotension. Arterioscler Thromb Vasc Biol 17: 2793–2800
Fulton D, Gratton JP, McCabe FJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC 1999 Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399: 597–601
Kitayama J, Kitazono T, Ibayashi S, Wakisaka M, Watanabe Y, Kamouchi M, Nagao T, Fujishima M 2000 Role of phosphatidyl 3-kinase in acetylcholine-induced dilation of rat basilar artery. Stroke 31: 2487–2493
Vlahos CJ, Matter WF, Hui KY, Brown RF 1994 A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269: 5241–5248
Qi JH, Claesson-Welsh L 2001 VEGF-induced activation of phosphoinositide 3-kinase is dependent on focal adhesion kinase. Exp Cell Res 263: 173–182
Lewis AB, Heymann MA, Rudolph AM 1976 Gestational changes in pulmonary vascular responses in fetal lambs in utero. Circ Res 39: 536–541
Cornfield DF, Chatfied BA, McQueston JA, McMurtry IF, Abman SH 1992 Effects of birth-related stimuli onl-arginine-dependent pulmonary vasodilation in ovine fetus. Am J Physiol 262: H1474–H1481
Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB 2000 In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol-3-kinase inhibitor (LY294002). Clin Cancer Res 6: 880–886
Acarregui MJ, Penisten ST, Goss KL, Ramirez K, Snyder JM 1999 Vascular endothelial growth factor gene expression in human fetal lung in vitro. Am J Respir Cell Mol Biol 20: 14–23
Bhatt AJ, Amin SB, Chess PR, Watkins RH, Maniscalco WM 2000 Expression of vascular endothelial growth factor and Flk-1 in developing and glucocorticoid treated mouse lung. Pediatr Res 47: 606–613
Yang R, Bunting S, Ko A, Keyt BA, Modi NB, Zioncheck TF, Ferrara N, Jun H 1998 Substantially attenuated hemodynamic responses to Escherichia coli-derived vascular endothelial growth factor given by intravenous infusion compared with bolus injection. J Pharmacol Exp Ther 284: 103–110
Hariawala MD, Horowitz JF, Esakof D, Sheriff DD, Walter DH, Dety B, Isner JM, Symes JF 1996 VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res 63: 77–82
Harada K, Friedman M, Lopez JJ, Wang Sy, Li J, Prasad PV, Pearlman JD, Edelman ER, Sellke FW, Simons M 1996 Vascular endothelial growth factor in chronic myocardial ischemia. Am J Physiol 270: H1791–H1802
Partovian C, Adnot S, Eddahibi S, Teiger E, Levame M, Dreyfus P, Raffenstin B, Frelin C 1998 Heart and lung VEGF mRNA expression in rats with monocrotaline- or hypoxia-induced pulmonary hypertension. Am J Physiol 275: H1948–H1956
Christou H, Yoshida A, Arthur V, Morita T, Kourembanas S 1998 Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension. Am J Respir Cell Mol Biol 18: 768–776
Parker TA, Le Cras TD, Kinsella JP, Abman SH 2000 Developmental changes in endothelial nitric oxide synthase expression and activity in ovine fetal lung. Am J Physiol 278: L202–L208
Accurso FJ, Wilkening RB 1988 Temporal response of the fetal pulmonary circulation to pharmacologic vasodilators. Proc Soc Exp Biol Med 187: 89–98
Accurso FJ, Albert B, Wilkening RB, Petersen RG, Meschia G 1986 Time-dependent response of fetal pulmonary blood flow to an increase in fetal oxygen tension. Respir Physiol 63: 43–52
Abman SH, Wilkening RB, Ward RM, Accurso FJ 1986 Adaptation of fetal pulmonary blood flow to local infusion of tolazoline. Pediatr Res 20: 1131–1135
Tucker A, Brown DT, Greenlees KJ 1982 Pulmonary and systemic vascular actions of tolazoline in anesthetized dogs. Pediatr Pharmacol 2: 231–243
Nakanishi S, Yano H, Matsuda Y 1995 Novel functions of phosphatidylinositol 3-kinase in terminally differentiated cells. Cell Signal 7: 545–557
Irani C, Goncharova EA, Hunter DS, Walker CL, Panettieri RA, Drymdkaya VP 2002 Phosphatidylinositol-3-kinase but not tuberin is required for PDGF-induced cell migration. Am J Physiol 282: L854–L862
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported in part by grants from the March of Dimes and the NIH (HL46481, HL68702).
Rights and permissions
About this article
Cite this article
Grover, T., Zenge, J., Parker, T. et al. Vascular Endothelial Growth Factor Causes Pulmonary Vasodilation through Activation of the Phosphatidylinositol-3-Kinase-Nitric Oxide Pathway in the Late-Gestation Ovine Fetus. Pediatr Res 52, 907–912 (2002). https://doi.org/10.1203/00006450-200212000-00016
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1203/00006450-200212000-00016
This article is cited by
-
Vascular endothelial growth factors and angiopoietins as new players in mastocytosis
Clinical and Experimental Medicine (2021)
-
Morphological and immunohistochemical phenotype of TCs in the intestinal bulb of Grass carp and their potential role in intestinal immunity
Scientific Reports (2020)
-
Is Diabetic Skeletal Fragility Associated with Microvascular Complications in Bone?
Current Osteoporosis Reports (2017)
-
Vasculaire endotheliale groeifactor en hypoxie-induceerbare factor 2α: drijvende krachten achter longmaturatie; belang voor respiratoir distress syndroom
Tijdschrift voor kindergeneeskunde (2005)
